Clascoterone vs RU58841? What’s more effective? Treatment 3/24/2026
Clascoterone and RU58841 are compared for effectiveness in treating hair loss. The discussion involves treatments like Minoxidil, finasteride, and RU58841.
View this post in the Community →
Similar Community Posts Join
6 / 252 resultscommunity Maintaining hair until Breezula without Fin
A 21-year-old male experienced side effects from topical finasteride and is seeking alternative treatments to maintain hair until Breezula is available. He is considering using minoxidil, Nizoral, micro-needling, and vitamin D supplementation, and may try CB or RU58841 if necessary.
community BREEZULA COVID UPDATE: Filing for Special Protocol Assessment with FDA
The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.
community Don't be inconsistent with Minoxidil, you will lose progress fast. My new plan for future.
Inconsistent minoxidil use led to hair loss, prompting a plan to resume consistent application with derma stamping, red light therapy, and DHT blockers like clascoterone or RU58841. The user avoids finasteride and dutasteride due to past side effects.
community Clascoterone 5% solution infographic
Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.
community Why Breezula Won’t Work for Everyone.
Breezula, a new topical hair loss treatment, is expected to be expensive, with an estimated cost of €300 per month, making it less accessible compared to cheaper alternatives like finasteride. Some users discuss the potential for cheaper generics from countries like China and India, while others debate the effectiveness and pricing strategy of Breezula compared to other treatments like minoxidil and RU58841.
community 29M, 5.5 months of: 0.5mg finasteride, 5% minoxidil, 1.5mm microneedling once a week and 20mg RU58841. No notable sides. I feel much better, and happy to have started treatment just in time. I just wish I started sooner! The dandruffy gunk you see is definitely propylene glycol from minoxidil :')
User shared 5.5-month progress using 0.5mg finasteride, 5% minoxidil, 1.5mm microneedling weekly, and 20mg RU58841, with positive results and no side effects. Others discussed their experiences, dosage adjustments, and the importance of age in treatment efficacy.
Related Research
6 / 101 results
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
De nouvelles thérapies promettent de mieux traiter la perte de cheveux due à l'alopécie androgénétique.
research Antiandrogens and Androgen Inhibitors
Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.
research Experimental and early investigational drugs for androgenetic alopecia
New hair loss treatments may include topical medications, injections, and improved transplant methods.
research Clascoterone: First Approval
Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.
research Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist
Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
research Clascoterone as a novel treatment for androgenetic alopecia
Clascoterone may be a promising treatment for hair loss.